151 related articles for article (PubMed ID: 17496161)
1. Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1.
Zhang Z; Liao B; Xu M; Jin Y
FASEB J; 2007 Oct; 21(12):3042-51. PubMed ID: 17496161
[TBL] [Abstract][Full Text] [Related]
2. Dnmt3b, de novo DNA methyltransferase, interacts with SUMO-1 and Ubc9 through its N-terminal region and is subject to modification by SUMO-1.
Kang ES; Park CW; Chung JH
Biochem Biophys Res Commun; 2001 Dec; 289(4):862-8. PubMed ID: 11735126
[TBL] [Abstract][Full Text] [Related]
3. An extended consensus motif enhances the specificity of substrate modification by SUMO.
Yang SH; Galanis A; Witty J; Sharrocks AD
EMBO J; 2006 Nov; 25(21):5083-93. PubMed ID: 17036045
[TBL] [Abstract][Full Text] [Related]
4. Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.
Spengler ML; Kennett SB; Moorefield KS; Simmons SO; Brattain MG; Horowitz JM
Cell Signal; 2005 Feb; 17(2):153-66. PubMed ID: 15494207
[TBL] [Abstract][Full Text] [Related]
5. BS69 undergoes SUMO modification and plays an inhibitory role in muscle and neuronal differentiation.
Yu B; Shao Y; Zhang C; Chen Y; Zhong Q; Zhang J; Yang H; Zhang W; Wan J
Exp Cell Res; 2009 Dec; 315(20):3543-53. PubMed ID: 19766626
[TBL] [Abstract][Full Text] [Related]
6. SUMO Ubc9 enzyme as a viral target.
Varadaraj A; Mattoscio D; Chiocca S
IUBMB Life; 2014 Jan; 66(1):27-33. PubMed ID: 24395713
[TBL] [Abstract][Full Text] [Related]
7. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor.
Tirard M; Almeida OF; Hutzler P; Melchior F; Michaelidis TM
Mol Cell Endocrinol; 2007 Mar; 268(1-2):20-9. PubMed ID: 17314004
[TBL] [Abstract][Full Text] [Related]
8. Repression of Smad4 transcriptional activity by SUMO modification.
Long J; Wang G; He D; Liu F
Biochem J; 2004 Apr; 379(Pt 1):23-9. PubMed ID: 14750902
[TBL] [Abstract][Full Text] [Related]
9. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2.
Zhang H; Smolen GA; Palmer R; Christoforou A; van den Heuvel S; Haber DA
Nat Genet; 2004 May; 36(5):507-11. PubMed ID: 15107848
[TBL] [Abstract][Full Text] [Related]
10. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
Wu YC; Roark AA; Bian XL; Wilson VG
Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639
[TBL] [Abstract][Full Text] [Related]
11. The reprogramming factor nuclear receptor subfamily 5, group A, member 2 cannot replace octamer-binding transcription factor 4 function in the self-renewal of embryonic stem cells.
Choi KW; Oh HR; Lee J; Lim B; Han YM; Oh J; Kim J
FEBS J; 2014 Feb; 281(4):1029-45. PubMed ID: 24341592
[TBL] [Abstract][Full Text] [Related]
12. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation.
Jakobs A; Koehnke J; Himstedt F; Funk M; Korn B; Gaestel M; Niedenthal R
Nat Methods; 2007 Mar; 4(3):245-50. PubMed ID: 17277783
[TBL] [Abstract][Full Text] [Related]
13. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation.
Ji Z; Degerny C; Vintonenko N; Deheuninck J; Foveau B; Leroy C; Coll J; Tulasne D; Baert JL; Fafeur V
Oncogene; 2007 Jan; 26(3):395-406. PubMed ID: 16862185
[TBL] [Abstract][Full Text] [Related]
15. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes.
Bossis G; Melchior F
Mol Cell; 2006 Feb; 21(3):349-57. PubMed ID: 16455490
[TBL] [Abstract][Full Text] [Related]
16. SUMO modification regulates the transcriptional activity of FLASH.
Alm-Kristiansen AH; Norman IL; Matre V; Gabrielsen OS
Biochem Biophys Res Commun; 2009 Sep; 387(3):494-9. PubMed ID: 19615980
[TBL] [Abstract][Full Text] [Related]
17. Covalent conjugation of the equine infectious anemia virus Gag with SUMO.
Wang J; Wen S; Zhao R; Qi J; Liu Z; Li W; An J; Wood C; Wang Y
Biochem Biophys Res Commun; 2017 May; 486(3):712-719. PubMed ID: 28342872
[TBL] [Abstract][Full Text] [Related]
18. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription.
Ling Y; Sankpal UT; Robertson AK; McNally JG; Karpova T; Robertson KD
Nucleic Acids Res; 2004; 32(2):598-610. PubMed ID: 14752048
[TBL] [Abstract][Full Text] [Related]
19. Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1.
Kim EJ; Park JS; Um SJ
Biochem Biophys Res Commun; 2008 Dec; 377(3):952-6. PubMed ID: 18955028
[TBL] [Abstract][Full Text] [Related]
20. The SUMO conjugating enzyme Ubc9 is required for inducing and maintaining stem cell pluripotency.
Tahmasebi S; Ghorbani M; Savage P; Gocevski G; Yang XJ
Stem Cells; 2014 Apr; 32(4):1012-20. PubMed ID: 24706591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
